文献速递膀胱癌与上尿路尿路上皮癌

联合策略增强卡介苗对非肌层浸润性膀胱癌疗效

Combination Strategies to Enhance Bacillus Calmette-Guérin Efficacy for Nonmuscle-Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2025-11-21

本文综述了高危非肌层浸润性膀胱癌(NMIBC)中卡介苗(BCG)耐药机制及联合策略。BCG治疗失败率可达半数,联合疗法旨在减少免疫抑制细胞群和免疫检查点阻断以克服耐药,但需权衡疗效、毒性与成本,尚需长期多臂试验直接比较。

要点

  • BCG是高危NMIBC的标准治疗,但高达半数患者治疗失败。
  • 联合策略针对免疫抑制细胞和检查点阻断以克服BCG耐药。
  • 联合设计无限,但 adoption 受重叠耐药机制、不良事件和经济负担挑战。

核心结论

  • 基于BCG的联合疗法已成为克服BCG耐药和促进持久应答的策略。
  • 联合设计无限,但 adoption 仍因重叠耐药机制、不良事件和经济负担而具有挑战性。
  • 需要长期多臂试验直接比较联合方案以提供肿瘤疗效、安全性和成本效益信息。

研究设计与样本

  • 叙述性综述,检索英语MEDLINE索引文章和摘要,主题为BCG耐药机制及增强高危NMIBC中BCG膀胱内治疗疗效的联合策略。

主要发现

  • 高危NMIBC的治疗选择在过去几年显著扩大。
  • 联合策略旨在减少免疫抑制细胞群(调节性T细胞、髓源性抑制细胞)和免疫检查点阻断,提供克服BCG耐药的机制。
  • 化疗免疫治疗和基于免疫治疗的联合代表膀胱保留策略,需权衡肿瘤疗效、毒性和成本效益。

临床怎么用

  • 临床可考虑基于BCG的联合策略以克服耐药和促进持久应答。
  • 选择联合方案时需权衡肿瘤疗效、毒性和成本效益。

局限性

  • 联合设计无限,但 adoption 受重叠耐药机制、不良事件和经济负担挑战。
  • 需要长期多臂试验进行直接比较分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bacillus Calmette-Guérin (BCG) is the standard of care therapy for high-risk nonmuscle-invasive bladder cancer (NMIBC). However, up to half of patients will experience treatment failure, and many face considerable adverse effects, which can lead to dose reduction and intolerance. Novel bladder-sparing approaches with favorable risk-to-benefit ratio are thus critical in NMIBC. MATERIALS AND METHODS: A narrative review of the literature was performed of English-language MEDLINE indexed articles and abstracts of resistance mechanisms to BCG and combination-based strategies to enhance the efficacy of BCG intravesical therapy in high-risk NMIBC. RESULTS: Treatment options for high-risk NMIBC have expanded considerably over the last few years. Combination strategies represent an opportunity to enhance the effectiveness of BCG and promote durable response. Combination therapies that aim to reduce immunosuppressive cellular populations (regulatory T cells, myeloid-derived suppressor cells) and immune checkpoint blockade offer mechanisms to overcome resistance to BCG therapy. Chemoimmunotherapy and immunotherapy-based combinations represent a bladder preservation strategy that needs to be weighed against oncological efficacy, toxicity, and cost-effectiveness. CONCLUSIONS: BCG-based combination therapies have emerged as a strategy to overcome BCG resistance and promote durable responses. Despite their promise, combination design is endless, and adoption remains challenging due to overlapping mechanisms of resistance, adverse events associated with systemic therapy and/or additional intravesical therapy, and financial burden. Long-term multiarm trials are needed for direct comparative analyses between combinations of agents to inform oncological efficacy, safety profile, and cost-effectiveness.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Wald G, Lang J, Alkazemi H, et al. Combination Strategies to Enhance Bacillus Calmette-Guérin Efficacy for Nonmuscle-Invasive Bladder Cancer. J Urol. 2025. PMID: 41270196. doi:10.1097/JU.0000000000004848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。